866-997-4948(US-Canada Toll Free)

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 84 Pages

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2017, provides an overview of the Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline landscape.

Polyarticular juvenile idiopathic arthritis (PJIA) affects five or more joints. PJIA causes inflammation in small joints of the fingers and hands, but weight-bearing joints and the jaw can also be affected. Symptoms include fevers, pink rash, eye inflammation, joint pain, joint swelling and problems with bone development and growth. Treatment includes painkillers, NSAID and disease-modifying anti-rheumatic drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 2, 1, 2, 9, 2 and 1 respectively.

Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Overview
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Companies Involved in Therapeutics Development
Biocon Ltd
Coherus BioSciences Inc
Livzon Pharmaceutical Group Inc
Momenta Pharmaceuticals Inc
Mycenax Biotech Inc
Oncobiologics Inc
Oncodesign SA
Panacea Biotec Ltd
Regeneron Pharmaceuticals Inc
Sandoz International GmbH
UCB SA
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Drug Profiles
abatacept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
certolizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sarilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Product Development Milestones
Featured News & Press Releases
Nov 02, 2016: Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept)
Aug 30, 2016: FDA approves Erelzi, a biosimilar to Enbrel
Jul 13, 2016: Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Biocon Ltd, H1 2017
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Coherus BioSciences Inc, H1 2017
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Livzon Pharmaceutical Group Inc, H1 2017
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Momenta Pharmaceuticals Inc, H1 2017
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Mycenax Biotech Inc, H1 2017
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncobiologics Inc, H1 2017
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncodesign SA, H1 2017
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Panacea Biotec Ltd, H1 2017
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Sandoz International GmbH, H1 2017
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by UCB SA, H1 2017
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *